Selenium speciation studies in cancer patients to evaluate the responses of biomarkers of selenium status to different selenium compounds.
Clinical trial
ICP-MS
Se-methylselenocysteine
Selenium speciation
Seleno-L-methionine
Sodium selenite
Journal
Analytical and bioanalytical chemistry
ISSN: 1618-2650
Titre abrégé: Anal Bioanal Chem
Pays: Germany
ID NLM: 101134327
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
received:
17
11
2023
accepted:
09
01
2024
revised:
04
01
2024
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
29
1
2024
Statut:
aheadofprint
Résumé
This work presents the first systematic comparison of selenium (Se) speciation in plasma from cancer patients treated orally with three Se compounds (sodium selenite, SS; L-selenomethionine, SeMet; or Se-methylselenocysteine, MSC) at 400 µg/day for 28 days. The primary goal was to investigate how these chemical forms of Se affect the plasma Se distribution, aiming to identify the most effective Se compound for optimal selenoprotein expression. This was achieved using methodology based on HPLC-ICP-MS after sample preparation/fractionation approaches. Measurements of total Se in plasma samples collected before and after 4 weeks of treatment showed that median total Se levels increased significantly from 89.6 to 126.4 µg kg
Identifiants
pubmed: 38286852
doi: 10.1007/s00216-024-05141-y
pii: 10.1007/s00216-024-05141-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Rayman MP. Selenium and human health. The Lancet. 2012;379(9822):1256–68. https://doi.org/10.1016/S0140-6736(11)61452-9 .
doi: 10.1016/S0140-6736(11)61452-9
Brigelius-Flohé R, Flohé L. Selenium and redox signaling. Arch Biochem Biophys. 2017;1(617):48–59.
doi: 10.1016/j.abb.2016.08.003
Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA. 1996;276(24):1957–63. https://doi.org/10.1001/jama.1996.03540240035027 .
doi: 10.1001/jama.1996.03540240035027
pubmed: 8971064
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301(1):39–51.
doi: 10.1001/jama.2008.864
pubmed: 19066370
Marshall JR, Burk RF, Ondracek RP, Hill KE, Perloff M, Davis W, et al. Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget. 2017;8(16):26312–22.
doi: 10.18632/oncotarget.15460
pubmed: 28412747
pmcid: 5432259
Brigelius-Flohe R, Sies H (Eds.). Diversity of selenium functions in health and disease. 1st ed. CRC Press. 2015. https://doi.org/10.1201/b18810 .
Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Knutsen HK, et al. Scientific opinion on the tolerable upper intake level for selenium. EFSA Journal. 2023;21(1):7704. https://doi.org/10.2903/j.efsa.2023.7704 .
Evans SO, Khairuddin PF, Jameson MB. Optimising selenium for modulation of cancer treatments. Anticancer Res. 2017;37(12):6497–509.
pubmed: 29187424
Jüliger S, Goenaga-Infante H, Lister TA, Fitzgibbon J, Joel SP. Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-κB inhibition and the rapid generation of other selenium species. Cancer Res. 2007;67(22):10984–92.
doi: 10.1158/0008-5472.CAN-07-0519
pubmed: 18006844
Evans SO, Jacobson GM, Goodman HJB, Bird S, Jameson MB. Comparative safety and pharmacokinetic evaluation of three oral selenium compounds in cancer patients. Biol Trace Elem Res. 2019;189(2):395–404.
doi: 10.1007/s12011-018-1501-0
pubmed: 30187284
Evans SO, Jacobson GM, Goodman HJB, Bird S, Jameson MB. Comparison of three oral selenium compounds in cancer patients: evaluation of differential pharmacodynamic effects in normal and malignant cells. J Trace Elem Med Biol. 2020;58:126446. https://doi.org/10.1016/j.jtemb.2019.126446 .
Roman M, Jitaru P, Barbante C. Selenium biochemistry and its role for human health. Metallomics. 2014;6:25–54. https://doi.org/10.1039/c3mt00185g .
Combs GF. Biomarkers of selenium status. Nutrients. 2015;7(4):2209–36.
doi: 10.3390/nu7042209
pubmed: 25835046
pmcid: 4425141
El-Bayoumy K, Sinha R, Richie J. Forms of selenium in cancer prevention. In: Brigelius-Flohe R, Sies H, editors. Diversity of Selenium Functions in Health and Disease. CRC Press; 2015. p. 137–70.
Burk RF, Hill KE, Motley AK. Plasma selenium in specific and non-specific forms. BioFactors. 2001;14(1–4):107–14.
doi: 10.1002/biof.5520140115
pubmed: 11568447
Busto MEDC, Oster C, Cuello-Nuñez S, Deitrich CL, Raab A, Konopka A, et al. Accurate quantification of selenoproteins in human plasma/serum by isotope dilution ICP-MS: focus on selenoprotein P. J Anal At Spectrom. 2016;31(9):1904–12.
doi: 10.1039/C6JA00122J
Vinceti M, Grill P, Malagoli C, Filippini T, Storani S, Malavolti M, et al. Selenium speciation in human serum and its implications for epidemiologic research: a cross-sectional study. Journal of Trace Elements in Medicine and Biology. 2015;31:1–10. https://doi.org/10.1016/j.jtemb.2015.02.001 .
doi: 10.1016/j.jtemb.2015.02.001
pubmed: 26004885
Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomark Prev. 2006;15(4):804–10.
doi: 10.1158/1055-9965.EPI-05-0950
Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, et al. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr. 2010;92(3):525–31.
doi: 10.3945/ajcn.2010.29642
pubmed: 20573787
pmcid: 2921536
Xia Y, Hill KE, Byrne DW, Xu J, Burk RF. Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr. 2005;81(4):829–834. https://doi.org/10.1093/ajcn/81.4.829 .
Persson-Moschos M, Alfthan G, Åkesson B. Plasma selenoprotein P levels of healthy males in different selenium status after oral supplementation with different forms of selenium. Eur J Clin Nutr. 1998;52(5):363–7.
doi: 10.1038/sj.ejcn.1600565
pubmed: 9630388
Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson AJ, et al. Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2010;91(4):923–31.
doi: 10.3945/ajcn.2009.28169
pubmed: 20181815
pmcid: 2844680
Combs GF, Jackson MI, Watts JC, Johnson LAK, Zeng H, Idso J, et al. Differential responses to selenomethionine supplementation by sex and genotype in healthy adults. Br J Nutr. 2012;107(10):1514–25.
doi: 10.1017/S0007114511004715
pubmed: 21936966
Brodin O, Hackler J, Misra S, Wendt S, Sun Q, Laaf E, et al. Selenoprotein P as biomarker of selenium status in clinical trials with therapeutic dosages of selenite. Nutrients. 2020;12(4):1–11.
doi: 10.3390/nu12041067
Hybsier S, Schulz T, Wu Z, Demuth I, Minich WB, Renko K, et al. Sex-specific and inter-individual differences in biomarkers of selenium status identified by a calibrated ELISA for selenoprotein P. Redox Biol. 2016;2017(11):403–14.
Deitrich CL, Cuello-Nunez S, Kmiotek D, Torma FA, Del Castillo Busto ME, Fisicaro P, et al. Accurate quantification of selenoprotein P (SEPP1) in plasma using isotopically enriched seleno-peptides and species-specific isotope dilution with HPLC coupled to ICP-MS/MS. Anal Chem. 2016;88(12):6357–65.
doi: 10.1021/acs.analchem.6b00715
pubmed: 27108743
Ward-Deitrich CL, Whyte E, Hopley C, Rayman MP, Ogra Y, Goenaga-Infante H. Systematic study of the selenium fractionation in human plasma from a cancer prevention trial using HPLC hyphenated to ICP-MS and ESI-MS/MS. Anal Bioanal Chem. 2020;413(2):331–44.
doi: 10.1007/s00216-020-02988-9
pubmed: 33140125
Infante HG, Joel SP, Warburton E, Hopley C, Hearn R, Jüliger S. Investigation of the selenium species distribution in a human B-cell lymphoma line by HPLC- and GC-ICP-MS in combination with HPLC-ESIMS/MS and GC-TOFMS after incubation with methylseleninic acid. J Anal At Spectrom. 2007;22(8):888–96.
doi: 10.1039/B708620B
Hughes DJ, Fedirko V, Jenab M, Schomburg L, Méplan C, Freisling H, et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. Int J Cancer. 2015;136(5):1149–61.
doi: 10.1002/ijc.29071
pubmed: 25042282
Kokarnig S, Tsirigotaki A, Wiesenhofer T, Lackner V, Francesconi KA, Pergantis SA, et al. Concurrent quantitative HPLC-mass spectrometry profiling of small selenium species in human serum and urine after ingestion of selenium supplements. Journal of Trace Elements in Medicine and Biology. 2015;29:83–90. https://doi.org/10.1016/j.jtemb.2014.06.012 .
doi: 10.1016/j.jtemb.2014.06.012
pubmed: 25063689
Flouda K, Dersch JM, Gabel-Jensen C, Stürup S, Misra S, Björnstedt M, et al. Quantification of low molecular weight selenium metabolites in human plasma after treatment with selenite in pharmacological doses by LC-ICP-MS. Anal Bioanal Chem. 2016;408(9):2293–301.
doi: 10.1007/s00216-016-9325-2
pubmed: 26832729
Lamarche J, Ronga L, Szpunar J, Lobinski R. Characterization and quantification of selenoprotein p: challenges to mass spectrometry. Int J Mol Sci. 2021;22(12):6283. https://doi.org/10.3390/ijms22126283 .
Konopka A, Winter D, Konopka W, Del Castillo E, Busto M, Nunez S, Goenaga-Infante H, et al. [Sec-to-Cys]selenoprotein-a novel type of recombinant, full-length selenoprotein standard for quantitative proteomics. J Anal At Spectrom. 2016;31(9):1929–38.
doi: 10.1039/C6JA00123H